The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.本發明提供用於治療患者之非小細胞肺癌之藥物的製備及治療患者之非小細胞肺癌之方法,該等藥物包含[5-(4-乙基-哌嗪-1-基甲基)-吡啶-2-基]-[5-氟-4-(7-氟-3-異丙基-2-甲基-3H-苯并咪唑-5-基)-嘧啶-2-基]-胺或其醫藥學上可接受之鹽,與如本文中進一步所述之抗VEGFR2抗體,較佳雷莫蘆單抗(ramucirumab)組合。
